November 29, 2017 09:36 AM EST
Financing

New back­ers Sofinno­va and Scopia bring Y-mAb's round to $80M for an­ti-can­cer drugs

Brittany Meiling

Two promi­nent in­vestors have squeezed in­to last month’s fi­nanc­ing round for Y-mAbs, a biotech launched by Gen­mab vet­er­ans, bring­ing an ad­di­tion­al $30 mil­lion to the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

FDA ap­proves Io­n­is’ treat­ment for a rare meta­bol­ic dis­or­der

A service from the Financial Times